Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

Anti-Human CD20/MS4A1 Antibody (SAA2209), PerCP

Catalog #:   FHC90764 Specific References (50) DATASHEET
Host species: Human
Isotype: IgG1, kappa
Applications: ELISA, FCM
Accession: P11836
Overview

Catalog No.

FHC90764

Species reactivity

Human

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Conjugation

PerCP

Target

B-lymphocyte surface antigen B1, Membrane-spanning 4-domains subfamily A member 1, MS4A1, Leukocyte surface antigen Leu-16, B-lymphocyte antigen CD20, Bp35, CD20

Endotoxin level

Please contact with the lab for this information.

Purification

Affinity chromatography.

Accession

P11836

Applications

ELISA, FCM

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.

Stability and Storage

Store at 4°C for 12 months. Protect from light. Do not freeze.

Clone ID

SAA2209

Data Image
References

Case Report: Unilateral relapsing primary central nervous system vasculitis-expanding the phenotype., PMID:40529356

Combinability of epcoritamab CD20-targeting T-cell engager and CD20 antibody-targeted therapies in B-cell non-Hodgkin lymphoma., PMID:40528731

Treatment Options for the Comorbidity of Multiple Sclerosis With Other Chronic Inflammatory Diseases., PMID:40526577

The anti-CD47 antibody magrolimab with obinutuzumab and venetoclax in relapsed or refractory indolent B-cell lymphomas., PMID:40524014

A Phase 2 Study of Obinutuzumab Combined with Lenalidomide in Previously Untreated High Tumor Burden Follicular Lymphoma., PMID:40517417

Evaluating the Role of CAR-T Cell Therapy in the Context of Current Therapy Options for Patients With Relapsed or Refractory Follicular Lymphoma., PMID:40516919

Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia., PMID:40515863

Native structure of the monoclonal therapeutic CD20 antibody ocrelizumab., PMID:40513927

Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients With Rheumatoid Arthritis., PMID:40512061

Role of Ocrelizumab in modulating gene and microRNA expression in multiple sclerosis., PMID:40510879

QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy., PMID:40500294

Factors for Rituximab Refractoriness in AQP4-IgG+ NMOSD: A Cohort Study., PMID:40492601

Potential use of the SARS-CoV-2 monoclonal antibody sipavibart in people with multiple sclerosis: definition of different patient archetypes from an Italian expert group perspective., PMID:40481170

Haemophagocytic lymphohistiocytosis (HLH) secondary to measles in an adult with a loss of post-vaccination humoral immunity following rituximab., PMID:40480240

Uveal melanoma following Bruton's tyrosine inhibitor use for the treatment of hematologic malignancies., PMID:40475129

The Role of Novel Immunomodulators in the Treatment of Autoimmune Hepatitis., PMID:40474885

Utilization of anti-CD20 antibodies for treatment of childhood nephrotic syndrome, 2010 to 2022., PMID:40473981

Advances in the treatment of ANCA-associated vasculitis., PMID:40473820

CD20×CD3 Bispecific Antibodies in B-NHL: A Review of Translational Science, Pharmacokinetics, Pharmacodynamics, and Dose Strategy in Clinical Research., PMID:40471801

CONFIDENCE treatment success: long-term real-world effectiveness and safety of ocrelizumab in Germany., PMID:40470489

Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)., PMID:40468805

[Severe late-onset neutropenia after rituximab administration]., PMID:40467890

Phase I/II Study of Subasumstat (TAK-981) in Combination With Rituximab in Relapsed/Refractory Non-Hodgkin Lymphoma., PMID:40467383

Targeting B Cells and Plasma Cells in Glomerular Disease., PMID:40465397

Oral lichen planus in a patient treated with anti-CD20 monoclonal antibodies., PMID:40465334

Predictive factors and nomogram for the risk of cytokine release syndrome with anti-CD3 × CD20 bispecific antibodies for Chinese patients., PMID:40464994

Pathogenesis, Diagnosis, Treatment, and Prognosis of CD20-Positive T and NK Cell Lymphoma: A Review., PMID:40460386

Hitting the Therapeutic Bullseye with Targeted Therapy for Patients with Chronic Lymphocytic Leukemia., PMID:40456120

Recent advances in monoclonal antibody development for treatment of B-cell acute lymphoblastic leukemia., PMID:40455243

Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study., PMID:40451284

Rituximab Use for Relapse Prevention in Anti-NMDAR Antibody-Mediated Encephalitis: A Multicenter Cohort Study., PMID:40446185

Rituximab for a rare pediatric case of concurrent thyroid eye disease and myasthenia gravis., PMID:40443484

Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study., PMID:40442445

Ocrelizumab-Induced Hemophagocytic Lymphohistiocytosis: A Case Report., PMID:40438805

Use of rituximab in connective tissue disease-associated interstitial lung disease: a narrative review., PMID:40438359

Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial., PMID:40434509

Vaccine-Induced Humoral and Cellular Response to SARS-CoV-2 in Multiple Sclerosis Patients on Ocrelizumab., PMID:40432100

COVID-19 Vaccination in Patients with Hematological Malignances., PMID:40432077

Dysregulated Adaptive Immune Responses to SARS-CoV-2 in Immunocompromised Individuals., PMID:40431250

Unsupervised Clustering of Cell Populations in Germinal Centers Using Multiplexed Immunofluorescence., PMID:40427719

Single-Agent and Associated Therapies with Monoclonal Antibodies: What About Follicular Lymphoma?, PMID:40427101

The Prognostic Impact of the Tumor Immune Microenvironment in Synovial Sarcoma: An Immunohistochemical Analysis Using Digital Pathology and Conventional Interpretation., PMID:40423041

Obinutuzumab-Induced Inflammatory Bowel Disease-Like Colitis., PMID:40421460

Severe Hypokalemic Paralysis Following Rituximab Infusion in a Patient With Microscopic Polyangitis., PMID:40416913

Antibody polymer drug conjugates with increased drug to antibody ratio: CD38-targeting nanomedicines for innovative therapy of relapsed lymphomas., PMID:40409372

Real-world observational study of infections in people treated with ocrelizumab for multiple sclerosis., PMID:40402264

Impact of SARS-CoV-2 infection on bispecific antibody treatment in patients with B-cell lymphoproliferative disorders., PMID:40402079

CXCL13 and CCL21 Induce Tertiary Lymphoid Structures and Enhance the Efficacy of Immunotherapy for Melanoma., PMID:40393449

Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy., PMID:40388905

Rituximab treatment in non-lupus full-house nephropathy: A case report., PMID:40371307

Datasheet
$ 270
Product specifications
50 T 270 100 T 446

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human CD20/MS4A1 Antibody (SAA2209), PerCP [FHC90764]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only